The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 03, 2023

Filed:

Jan. 12, 2018
Applicants:

Radiomedix Inc., Houston, TX (US);

Orano Med, Courbevoie, FR;

Inventors:

Izabela Tworowska, Houston, TX (US);

Nilesh Wagh, Houston, TX (US);

Ebrahim S. Delpassand, Houston, TX (US);

Federico Rojas-Quijano, Bedford, TX (US);

Paul Jurek, Red Oak, TX (US);

Garry E. Kiefer, Richardson, TX (US);

Tania A. Stallons, Wylie, TX (US);

Amal Saidi, Thomon-les-Bains., FR;

Julien Torgue, Gaithersburg, MD (US);

Assignees:

RADIOMEDIXINC., Houston, TX (US);

ORANO MED, Courbevoie, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 51/08 (2006.01); A61P 35/00 (2006.01); A61K 51/04 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/18 (2017.01); A61K 47/22 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 51/083 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01); A61K 47/22 (2013.01); A61K 51/0482 (2013.01); A61K 51/088 (2013.01); A61P 35/00 (2018.01); A61K 45/06 (2013.01);
Abstract

A cancer targeting composition, kit, and method for treatment of cancer cells overexpressing somatostatin receptors is disclosed. The composition includes a radioisotope, a chelator, and a targeting moiety. The chelator includes a nitrogen ring structure including a tetraazacyclododecane, a triazacyclononane, and/or a tetraazabicyclo [6.6.2] hexadecane derivative. The targeting moiety includes a somatostatin receptor targeting peptide. The somatostatin receptor targeting peptide includes an octreotide derivative. The targeting moiety is chelated to the radioisotope by the chelator whereby the cancer cells are targeted for elimination.


Find Patent Forward Citations

Loading…